Investor Relations

2015 News Releases

Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013
DateTitle 
12/30/15KemPharm, Inc. Expands Pain Therapy Pipeline With Discovery of KP746
Novel Prodrug of Oxymorphone Adds New Asset to KemPharm’s Advancing Abuse-Deterrent Product Portfolio CORALVILLE, Iowa, Dec. 30, 2015 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, announced today plans to initiate development of KP746, a recently identified oral prodrug of oxymorphone.  Oxymorphone, marketed under the brand name Opana®, is a commonly prescribed medication fo... 
Printer Friendly Version
12/15/15KemPharm Submits NDA for KP201/APAP and Requests Priority Review From the FDA
If Approved, KP201/APAP May be the First Immediate Release Hydrocodone Combination Product Candidate for the Treatment of Acute Pain Designed to Address Opioid Abuse and Misuse CORALVILLE, Iowa, Dec. 15, 2015 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), today announced that it has submitted a New Drug Application (NDA) under Section 505(b)(2) of the Federal Food, Drug and Cosmetic Act for KP201/APAP to the U.S. Food and Drug Administration (FDA) and has requested priority review.  If pri... 
Printer Friendly Version
12/03/15KemPharm, Inc. to Present at the Oppenheimer 26th Annual Healthcare Conference in New York, NY
CORALVILLE, Iowa, Dec. 3, 2015 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, announced today that its president and chief executive officer, Travis C. Mickle, Ph.D., will present at the Oppenheimer 26th Annual Healthcare Conference being held in New York, NY, on December 8-9, 2015. Details of KemPharm's presentation are as follows: Date: Tuesday,... 
Printer Friendly Version
11/12/15KemPharm, Inc. Reports Q3 2015 Results
Conference Call and Live Audio Webcast Scheduled for Today at 4:30 p.m. ET Recent Clinical Development Highlights: Completed Human Abuse Liability Program for KP201/APAP, KemPharm's prodrug of hydrocodone (KP201), formulated in combination with acetaminophen (APAP) Reported positive results from second intranasal human abuse liability clinical trial of KP201/APAP Reported positive data demonstrating tamper-resistant properties of KP201/APAP Anticipate filing a new d... 
Printer Friendly Version
11/05/15KemPharm, Inc. to Report Third Quarter 2015 Results
Conference Call and Live Audio Webcast Scheduled for November 12, 2015, 4:30 p.m. ET CORALVILLE, Iowa, Nov. 5, 2015 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, announced today that the Company will host a conference call and live audio webcast on Thursday, November 12, 2015, at 4:30 p.m. ET, to discuss its corporate and financial results for the quarter ended September 30, 2... 
Printer Friendly Version
10/21/15KemPharm, Inc. Completes Human Abuse Liability Program for KP201/APAP
Positive Results From Second Intranasal Human Abuse Liability Clinical Trial Reaffirm Properties of KP201/APAP Conference Call and Live Audio Webcast Scheduled for Today at 5:00 p.m. ET CORALVILLE, Iowa, Oct. 21, 2015 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today announced the completion of its human abuse liability program of KP201, KemPharm's prodrug of hydroco... 
Printer Friendly Version
10/13/15KemPharm Enhances U.S. and Global Intellectual Property Estate
KemPharm Receives Patent From the USPTO for Novel Prodrug of Methylphenidate, KP415, Additional USPTO Patent Protection for KP201, and Multiple Ex-US Patents for KP511 and KP303 CORALVILLE, Iowa, Oct. 13, 2015 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today announced several enhancements to KemPharm's U.S. and global intellectual property estate governing its portfolio of ... 
Printer Friendly Version
09/30/15KemPharm Reports Positive Data Demonstrating Tamper-Resistant Properties of KP201/APAP
Results Indicate That Prodrug Design of KP201/APAP Significantly Hinders Traditional Means of Abuse, Including Extraction, Injection and Smoking CORALVILLE, Iowa, Sept. 30, 2015 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today reported positive results from three distinct studies designed to evaluate the tamper-resistant properties of its lead opioid prodrug KP201/APAP, Kem... 
Printer Friendly Version
09/24/15KemPharm Expands Its Abuse-Deterrent Opioid Pipeline With New Acetaminophen-Free, Immediate Release Hydrocodone and Immediate Release Oxycodone Prodrug Product Candidates
Provides Updates on Clinical Development Pipeline and Anticipated NDA Filings CORALVILLE, Iowa, Sept. 24, 2015 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, announced today that KemPharm has initiated the development of an acetaminophen (APAP)-free formulation of its immediate release (IR) hydrocodone product, KP201, adding to its hydrocodone prodrug pipeline of product candid... 
Printer Friendly Version
09/23/15KemPharm to Highlight the Potential of Prodrugs at the 9th Annual Pain & Migraine Therapeutics Summit
Presentation by Sven Guenther, Ph.D., KemPharm's EVP of Research & Development, to Showcase Prodrugs and the Clinical Progress of KP201/APAP and KP511 CORALVILLE, Iowa, Sept. 23, 2015 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, announced today that Sven Guenther, Ph.D., Executive Vice President of Research & Development, will be a featured presenter at the 9th Annual... 
Printer Friendly Version
09/08/15KemPharm Data to be Presented at PAINWeek 2015
Posters Highlight Data on Opioid Abuse Prevalence, and the Advantages of Prodrugs and KP201/APAP in Preventing Abuse and Misuse CORALVILLE, Iowa, Sept. 8, 2015 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, announced today that four posters related to the development of its investigational prodrug of hydrocodone (KP201), combined with acetaminophen (APAP), together referred to ... 
Printer Friendly Version
08/13/15KemPharm, Inc. Announces Positive Data From Intranasal Human Abuse Liability Study of KP201/APAP; Reports Q2 2015 Results
Results from First of Two Intranasal Human Abuse Liability Clinical Studies Indicate KP201 Exhibits Significantly Lower Exposure to Hydrocodone When Administered Intranasally Conference Call and Live Audio Webcast Scheduled for Today at 4:30 p.m. ET Recent Clinical Development Highlights: Reports positive pharmacokinetic data from first of two KP201 intranasal human abuse liability clinical trials Reported positive data from oral human abuse liability clinical trial of KP2... 
Printer Friendly Version
08/13/15KemPharm, Inc. to Report Pharmacokinetic Data From Intranasal Human Abuse Liability Study on Second Quarter Conference Call
Conference Call and Live Audio Webcast Today at 4:30 p.m. ET CORALVILLE, Iowa, Aug. 13, 2015 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, announced today that the Company will report the results from its intranasal human abuse liability study of KP201/APAP on today's scheduled 4:30 p.m. ET call to review KemPharm's corporate and financial results for the second quarter ended ... 
Printer Friendly Version
08/06/15KemPharm, Inc. to Report Q2 2015 Results
Conference Call and Live Audio Webcast Scheduled for August 13, 2015, 4:30 p.m. ET CORALVILLE, Iowa, Aug. 6, 2015 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, announced today that the Company will host a conference call and live audio webcast on Thursday, August 13, 2015, at 4:30 p.m. ET, to discuss its corporate and financial results for the quarter ended June 30, 2015. ... 
Printer Friendly Version
08/04/15KemPharm, Inc. to Present at Canaccord Genuity 35th Annual Growth Conference
CORALVILLE, Iowa, Aug. 4, 2015 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today announced that Travis C. Mickle, Ph.D., President and CEO of KemPharm, will present at the Canaccord Genuity 35th Annual Growth Conference being held August 12-13, 2015, at the InterContinental Boston Hotel. Event:   Canaccord Genuity 35th Annual Growth Confe... 
Printer Friendly Version
06/25/15KemPharm, Inc. Announces Changes to Senior Leadership to Target Strategic Opportunities
Rusty Johnson Named as Newly Created Chief Business Officer; LaDuane Clifton Appointed as Chief Financial Officer CORALVILLE, Iowa, June 25, 2015 (GLOBE NEWSWIRE) -- KemPharm, Inc. (Nasdaq:KMPH), a clinical-stage specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today announced the appointment of Gordon K. "Rusty" Johnson to the new role of Chief Business Officer and the promotion of R. LaDuane Clifton to Chief Financial Officer. These changes ar... 
Printer Friendly Version
06/11/15KemPharm, Inc. Reports Positive Data From Oral Human Abuse Liability Clinical Trial of KP201/APAP
Company to Host Conference Call and Live Audio Webcast Today at 8:30 a.m. ET CORALVILLE, Iowa, June 11, 2015 (GLOBE NEWSWIRE) -- KemPharm, Inc. (Nasdaq:KMPH), a clinical-stage specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today announced positive data from its oral human abuse liability clinical trial of KP201/APAP, the Company's most advanced product candidate. KP201/APAP is an immediate release combination of KP201, the Company's prodrug of... 
Printer Friendly Version
05/27/15KemPharm, Inc. Reports Q1 2015 Results
Conference Call and Live Audio Webcast Scheduled for Today at 4:30 p.m. ET Recent Highlights: Completed pre-NDA meeting for KP201/APAP with FDA on May 20, 2015 Initial public offering closed on April 21, 2015 Appointed David M. Tierney to Board of Directors on March 3, 2015 Appointed Tracy M. Woody as Chief Commercial Officer on February 18, 2015 CORALVILLE, Iowa, May 27, 2015 (GLOBE NEWSWIRE) -- KemPharm, Inc. (Nasdaq:KMPH), a clinical-stage specialty pharmac... 
Printer Friendly Version
05/21/15KemPharm Completes Pre-NDA Meeting With FDA for KP201/APAP
Company Remains on Track for NDA Submission in Second Half of 2015 CORALVILLE, Iowa, May 21, 2015 (GLOBE NEWSWIRE) -- KemPharm, Inc. (Nasdaq:KMPH), a clinical-stage specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, announced today that the Company concluded a pre-New Drug Application ("NDA") meeting with the U.S. Food and Drug Administration ("FDA") for its lead pain candidate, KP201/APAP (benzhydrocodone hydrochloride and acetaminophen). The ... 
Printer Friendly Version
05/19/15KemPharm's KP201/APAP Featured at the 2015 Abuse Deterrent Formulations Summit
KemPharm's Executive Vice President of R&D, Sven Guenther, Ph.D., to Discuss the Potential of Prodrug Technologies as a Deterrent to Opioid Tampering and Abuse CORALVILLE, Iowa, May 19, 2015 (GLOBE NEWSWIRE) -- KemPharm, Inc. (Nasdaq:KMPH), a clinical-stage specialty pharmaceutical company engaged in the discovery and development of proprietary new molecular entity ("NME") prodrugs, announced today that its Executive Vice President of Research and Development, Sven Guenther, Ph.D., will pre... 
Printer Friendly Version
05/18/15KemPharm, Inc. to Report Q1 2015 Results
Conference Call and Live Audio Webcast Scheduled for May 27, 2015, 4:30 p.m. ET CORALVILLE, Iowa, May 18, 2015 (GLOBE NEWSWIRE) -- KemPharm, Inc. (Nasdaq:KMPH), a clinical-stage specialty pharmaceutical company engaged in the discovery and development of proprietary new molecular entity ("NME") prodrugs, announced today that the Company will host a conference call and live audio webcast on Wednesday, May 27, 2015, at 4:30 p.m. ET, to discuss its corporate and financial results for the quarter e... 
Printer Friendly Version
04/15/15KemPharm Announces Pricing of Initial Public Offering
CORALVILLE, Iowa, April 15, 2015 (GLOBE NEWSWIRE) -- KemPharm, Inc., a clinical-stage specialty pharmaceutical company engaged in the discovery and development of proprietary new molecular entity (NME) prodrugs, announced today the pricing of its initial public offering of 5,090,909 shares of its common stock at a price to the public of $11.00 per share. The shares are expected to begin trading on The NASDAQ Global Market under the ticker symbol "KMPH" on April 16, 2015. All of the common stock ... 
Printer Friendly Version
03/10/15KemPharm, Inc. Appoints David S. Tierney, MD to Board of Directors
Coralville, IA – March 10, 2015 – KemPharm, Inc., a clinical-stage specialty pharmaceutical company engaged in the discovery and development of proprietary new molecular entity (NME) prodrugs, announced today the appointment of David S. Tierney, M.D. to its Board of Directors. Dr. Tierney currently serves as President & Chief Executive Officer of Icon Bioscience, Inc., a privately held specialty biopharmaceutical company focused on the development and commercialization of unique ophthalmic p... 
Printer Friendly Version
03/04/15KemPharm, Inc. Appoints Tracy M. Woody as Chief Commercial Officer
20-Year Pharmaceutical Sales & Marketing Executive to Spearhead Commercialization Strategy for KemPharm's NME Prodrug Pipeline, including KP201/APAPCoralville, IA – March 4, 2015 – KemPharm, Inc., a clinical-stage specialty pharmaceutical company engaged in the discovery and development of proprietary new molecular entity (NME) prodrugs, announced today the appointment of Tracy M. Woody as Chief Commercial Officer. Ms. Woody brings to KemPharm more than 20 years of commercial experience buil... 
Printer Friendly Version